Neuland Laboratories Limited has informed the Exchange about General Updates
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA inspected Neuland Laboratories' Unit 2 manufacturing facility in Pashamylaram, Sangareddy District, from April 28 to May 2, 2025. At the end of the inspection, the FDA issued a Form 483 with a single observation related to building and facility management. The company has stated it will respond to the observation within the stipulated timelines set by the FDA. No data integrity or critical process-related observations were mentioned in the filing.
A single minor observation on Form 483 is generally considered routine and not a major red flag for pharmaceutical companies. Shareholders should note that the company's response and any subsequent classification (like an EIR or warning letter) will be the next key updates to watch.